FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387041302> ?p ?o ?g. }

• W4387041302 endingPage "S26" @default.
• W4387041302 startingPage "S25" @default.
• W4387041302 abstract "Background: Hepatic encephalopathy (HE) is a frequent complication of liver cirrhosis and a common reason for hospital admission and readmission. There are no available risk scores to predict the development of HE, but the Bilirubin-Albumin-Beta-Blocker-Statin (BABS) score has been proposed as a tool for risk stratification. The aim of the study was to validate the BABS score for the prediction of HE in patients with liver cirrhosis. Methods: Patients from Mainz, Germany with liver cirrhosis but without baseline HE (n = 398) were included. The primary outcome was the development of HE, defined as HE grade ≥1 according to the West Haven Criteria and mean follow up time was 514 days (range: 14-1280 days). Risk scores were constructed with baseline data resulting in a BABS score of <-10 (low), -9 to 20 (intermediate), and ≥21 (high). Kaplan-Meier curves were modelled showing time to HE and Cox regressions were performed to estimate hazard ratios. Results: The mean age was 59 years (±10.3 SD), 40% were women and the mean level of bilirubin and albumin were 2.20 mg/dL (±3.12 SD) and 2.4 mg/dL (±0.69 SD), respectively. Half of the patients used beta-blockers and 10% of patients used statins. The mean BABS score was 11.7 (±18.4 SD) and 55 (13.8%) patients developed HE. Patients who developed HE had higher levels of bilirubin and lower levels of albumin compared to those who did not develop HE. The use of beta-blockers was higher in patients developing HE, while the use of statins was lower. Patients who developed HE had a higher BABS score of 27.8 (±14.5 SD) compared to patients who did not develop HE 9.1 (±17.69 SD) (P<0.0001). None of the patients with a BABS score <-10 developed HE, 10% of patients with a score between -9 and 20 developed HE and 30% of patients with a score ≥21 developed HE. Conclusion: These data demonstrates that the BABS score can be used for risk stratification of HE (see Figures 1 and 2).Figure 1.: Proportion of patients developing HE stratified by risk score.Figure 2.: Kaplan-Meier curve of stratified risk scores for development of HE." @default.
• W4387041302 created "2023-09-27" @default.
• W4387041302 creator A5003084621 @default.
• W4387041302 creator A5016520701 @default.
• W4387041302 creator A5051134694 @default.
• W4387041302 creator A5055434972 @default.
• W4387041302 creator A5066388531 @default.
• W4387041302 creator A5081985314 @default.
• W4387041302 creator A5085131013 @default.
• W4387041302 date "2023-09-01" @default.
• W4387041302 modified "2023-09-27" @default.
• W4387041302 title "P39 A Validation of the Bilirubin-Albumin-Betablocker-Statin Score to Predict the Development of Hepatic Encephalopathy in Patients With Liver Cirrhosis" @default.
• W4387041302 doi "https://doi.org/10.14309/01.ajg.0000948440.77116.52" @default.
• W4387041302 hasPublicationYear "2023" @default.
• W4387041302 type Work @default.
• W4387041302 citedByCount "0" @default.
• W4387041302 crossrefType "journal-article" @default.
• W4387041302 hasAuthorship W4387041302A5003084621 @default.
• W4387041302 hasAuthorship W4387041302A5016520701 @default.
• W4387041302 hasAuthorship W4387041302A5051134694 @default.
• W4387041302 hasAuthorship W4387041302A5055434972 @default.
• W4387041302 hasAuthorship W4387041302A5066388531 @default.
• W4387041302 hasAuthorship W4387041302A5081985314 @default.
• W4387041302 hasAuthorship W4387041302A5085131013 @default.
• W4387041302 hasBestOaLocation W43870413021 @default.
• W4387041302 hasConcept C126322002 @default.
• W4387041302 hasConcept C151956035 @default.
• W4387041302 hasConcept C207103383 @default.
• W4387041302 hasConcept C2776125364 @default.
• W4387041302 hasConcept C2776839432 @default.
• W4387041302 hasConcept C2777214474 @default.
• W4387041302 hasConcept C2777513400 @default.
• W4387041302 hasConcept C2780325230 @default.
• W4387041302 hasConcept C44249647 @default.
• W4387041302 hasConcept C71924100 @default.
• W4387041302 hasConcept C90924648 @default.
• W4387041302 hasConceptScore W4387041302C126322002 @default.
• W4387041302 hasConceptScore W4387041302C151956035 @default.
• W4387041302 hasConceptScore W4387041302C207103383 @default.
• W4387041302 hasConceptScore W4387041302C2776125364 @default.
• W4387041302 hasConceptScore W4387041302C2776839432 @default.
• W4387041302 hasConceptScore W4387041302C2777214474 @default.
• W4387041302 hasConceptScore W4387041302C2777513400 @default.
• W4387041302 hasConceptScore W4387041302C2780325230 @default.
• W4387041302 hasConceptScore W4387041302C44249647 @default.
• W4387041302 hasConceptScore W4387041302C71924100 @default.
• W4387041302 hasConceptScore W4387041302C90924648 @default.
• W4387041302 hasIssue "9S" @default.
• W4387041302 hasLocation W43870413021 @default.
• W4387041302 hasOpenAccess W4387041302 @default.
• W4387041302 hasPrimaryLocation W43870413021 @default.
• W4387041302 hasRelatedWork W2382369664 @default.
• W4387041302 hasRelatedWork W2389253920 @default.
• W4387041302 hasRelatedWork W2389359564 @default.
• W4387041302 hasRelatedWork W2391762134 @default.
• W4387041302 hasRelatedWork W2392950474 @default.
• W4387041302 hasRelatedWork W2737137833 @default.
• W4387041302 hasRelatedWork W2895862229 @default.
• W4387041302 hasRelatedWork W3000131867 @default.
• W4387041302 hasRelatedWork W3030351087 @default.
• W4387041302 hasRelatedWork W4376138777 @default.
• W4387041302 hasVolume "118" @default.
• W4387041302 isParatext "false" @default.
• W4387041302 isRetracted "false" @default.
• W4387041302 workType "article" @default.